Global Liposomal Doxorubicin Market By Product Type (J&J [Doxil/Caelyx], Sun Pharma [Lipodox], Teva [Myocet], Others), By Application (Liver Cancer, Breast cancer, Kaposi sarcoma, and Other applications), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Liposomal Doxorubicin Market Overview

The global Liposomal Doxorubicin Market was worth USD 1,168.4 million in 2021. It is observed to grow at a CAGR of 7.3%, between 2023 and 2032.

Market growth will be driven by the growing demand for electricity from clean energy sources. Market growth is expected to be boosted by a growing focus on projects that are related to distributed power and utility in the forecasted year.

Global Liposomal Doxorubicin Market Scope:

Product type analysis

The segment of J&J (Doxil/Caelyx) held 55.3% of the revenue share in 2021. This market is driven by the high mortality and incidence of ovarian carcinoma. In the next few years, the market will be driven by the demand for Caelyx or Doxil as another treatment for ovarian cancer.

One of the main factors that will drive demand is the increasing number of generic formulations approved the address crisis of saving lives with medicines. Other products included DOXT SL (Sun Pharma, Inc.) and some other segments.

The market is being negatively affected because of very less approval in the U.S. for any other products, except Lipodox and Doxil. The demand for products in Europe, which is the second-largest segment will be driven by the availability of Nudoxa, DOXTSL injections, and Evacet tablets. This market is also characterized by the availability of several pipeline products that are awaiting approval from the FDA of the U.S.A or the agency of medicines in Europe.

Application analysis

Breast cancer had a 23.4% share of revenue in 2021. One of the main factors driving the increase in breast cancer treatment is the advancement of drug formulations. In 2021, ovarian carcinoma held the second spot. It is projected to grow at a rate of 6.2% over the forecasted time.

Market growth is expected to be driven by the growing use of chemotherapy drugs and the increasing demand for therapy drugs is also targeted and also the growing investment of private players in this area. Recent years have shown that liposomal Doxorubicin is the most efficient chemotherapeutic drug to treat hepatocellular carcinoma. Caelyx, Thermodox, and other products are all suitable for this condition, and in the next few years, the market will be positively impacted by the government’s increasing efforts to improve manufacturing quality and quantity.

Кеу Маrkеt Ѕеgmеntѕ

By Product Type

• Sun Pharma [Lipodox]
• Teva [Myocet]
• J&J [Doxil/Caelyx]
• Other Types

By Application

• Kaposi
• Breast Cancer
• Liver Cancer
• Other Applications

Market Dynamics:

The U.S. FDA approved a generic liposomal doxorubicin formulation to treat ovarian cancer. The import of the drug was also approved in the U.S. under the “exercise enforcement discretion”, which is the largest marketplace for doxorubicin formula. This has resulted in a large import of doxorubicin HCL liposome injections. This is expected to propel the market. The growth can also be attributed to the growing involvement of important private players in reducing redundancies and complexity in the global supply chains.

Regional Analysis

North America was the dominant market, accounting for over 53.4% of global revenue in 2021. This is due to the high incidence of liver cancers, ovary cancers, and breast cancer, as well as sarcomas. The region is also characterized by high levels of patient awareness and advanced healthcare facilities. Market growth is also influenced by the strong reimbursement system and regulatory framework.

North America region is expected to observe a massive growth of 9.4% over the forecast period. Key factors which are responsible for the rapid growth during the forecast period from 2023 to 2032 include enlarging the patient pool, increasing awareness of efficient drug alternatives, and investments from private and public bodies.

Key Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

Маrkеt Кеу Рlауеrѕ:

• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson, Merck & Co.
• Cipla, Inc.
• Cadila Pharmaceuticals
• SRS Pharmaceuticals Pvt. Ltd
• Other Key Players

For the Liposomal Doxorubicin Market research study, the following years have been considered to estimate the market size: